The Chiesi Group was awarded yesterday at the EURORDIS Black Pearl ceremony held in Brussels, with the Company Award for Innovation. The EURORDIS Black Pearl Award is an annual event held in Brussels to recognise the outstanding achievements and exceptional work of people making a difference for the rare disease community. Taking place in February to mark the occasion of Rare Disease Day, this event celebrates the inspirational qualities of people living with a rare disease along with those who go that extra mile to make a difference to their lives.
Chiesi was nominated for its strong commitment to rare diseases and its support to policy development, as well as its strong pipeline for bringing to market a wide number of treatments, including products for extremely rare diseases. "Chiesi Group is delighted to receive this award, a real sign of recognition that the Company is going in the right direction" commented Ugo Di Francesco, CEO, Chiesi Group. "This is the fulfilment of a journey made of commitment and dedication and gives us further motivation to continue this path to improve patients' good health & wellbeing, and generate a meaningful and positive impact in patients' quality life".
It is over 10 years since Chiesi has accepted the challenge posed by rare diseases, contributing to the birth and development of "Holostem Terapie Avanzate". Collaboration with Holostem has generated a stem cell therapy platform which has delivered the first and only EMA approved stem cell therapy for the treatment of moderate to severe limbal stem cell deficiency (LSCD) due to physical or chemical ocular burns. Chiesi's commitment has expanded over time into the field of inherited metabolic diseases.
Over the past few years the Company has been building a portfolio of products that may bring value to the Health Care System and change the lives of patients suffering from rare and ultra-rare lysosomal diseases.
The european organisation for rare diseases (EURODIS) was found in 1997 with the goal to improve the lives of peolpe who are living with a rare disease.
